See more : Enteq Technologies Plc (NTQ.L) Income Statement Analysis – Financial Results
Complete financial analysis of MGC Pharmaceuticals Limited (MGCLF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MGC Pharmaceuticals Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Verizon Communications Inc (VZ.NE) Income Statement Analysis – Financial Results
- Etruscus Resources Corp. (ETRUF) Income Statement Analysis – Financial Results
- Innovative Industrial Properties, Inc. (IIPR) Income Statement Analysis – Financial Results
- Shenzhen Topway Video Communication Co., Ltd (002238.SZ) Income Statement Analysis – Financial Results
- Philux Global Group Inc. (PHIL) Income Statement Analysis – Financial Results
MGC Pharmaceuticals Limited (MGCLF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://mgcpharma.com.au
About MGC Pharmaceuticals Limited
MGC Pharmaceuticals Limited, a bio-pharma company, develops and supplies phytomedicines in worldwide. The company produces and supplies medicinal cannabis products; and non-cannabis phytomedicines. Its principal product candidates include CimetrA, which is in phase III clinical trial for the symptomatic treatment of early COVID-19; CannEpil, a phase IIb cannabis-based therapy for drug-resistant Epilepsy; and CogniCann that is in phase II clinical trial for the symptomatic relief of Dementia. The company also provides ArtemiC range of products and cannabinoid products, as well as non-pharma products. In addition, it offers consulting services, including clinical research services. The company was formerly known as Erin Resources Limited and changed its name to MGC Pharmaceuticals Limited in December 2015. MGC Pharmaceuticals Limited was founded in 2014 and is based in West Perth, Australia.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.39M | 4.65M | 2.96M | 2.03M | 656.24K | 296.81K | 120.24K | 2.20K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 351.66K | 2.11M | 1.91M | 2.63M | 0.00 |
| Cost of Revenue | 1.94M | 3.01M | 1.65M | 1.90M | 356.64K | 119.34K | 158.07K | 15.01K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 1.45M | 1.63M | 1.31M | 130.15K | 299.60K | 177.47K | -37.83K | -12.81K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 351.66K | 2.11M | 1.91M | 2.63M | 0.00 |
| Gross Profit Ratio | 42.82% | 35.15% | 44.23% | 6.40% | 45.65% | 59.79% | -31.46% | -583.25% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% |
| Research & Development | 1.99M | 4.24M | 5.86M | 5.37M | 2.87M | 951.32K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 12.13M | 8.28M | 5.73M | 6.61M | 2.61M | 3.36M | 4.27M | 683.09K | 510.09K | 244.11K | 362.77K | 101.01K | 98.33K | 1.43M | 1.70M | 1.39M | 1.03M | 0.00 |
| Selling & Marketing | 926.91K | 949.83K | 583.19K | 562.13K | 574.98K | 612.76K | 204.76K | 240.26K | 36.39K | 12.33K | 9.38K | 3.16K | 4.83K | 223.63K | 326.02K | 477.93K | 462.40K | 0.00 |
| SG&A | 13.06M | 9.23M | 6.31M | 6.61M | 3.19M | 3.97M | 4.47M | 923.35K | 546.48K | 256.43K | 372.16K | 104.17K | 103.17K | 1.65M | 2.03M | 1.86M | 1.49M | 0.00 |
| Other Expenses | -578.77K | -1.18M | -425.12K | 524.32K | 9.46M | -1.79M | -1.29M | -1.78M | -6.51K | 1.60K | -27.35K | 15.00K | 28.39K | 951.09K | 155.02K | 27.97K | 2.59M | 0.00 |
| Operating Expenses | 17.05M | 15.08M | 13.38M | 12.55M | 9.34M | 7.44M | 7.28M | 4.36M | 3.80M | 5.35M | 765.21K | 343.94K | 252.45K | 3.08M | 3.64M | 3.55M | 2.68M | 0.00 |
| Cost & Expenses | 24.26M | 18.10M | 15.03M | 14.45M | 9.70M | 7.56M | 7.44M | 4.38M | 3.80M | 5.35M | 765.21K | 343.94K | 252.45K | 3.08M | 3.64M | 3.55M | 2.68M | 0.00 |
| Interest Income | 240.00 | 300.00 | 7.63K | 12.34K | 201.85K | 191.59K | 127.26K | 46.03K | 5.89K | 7.10K | 25.66K | 38.06K | 7.12K | 759.08K | 390.37K | 27.97K | 40.94K | 0.00 |
| Interest Expense | 257.40K | 190.05K | 369.14K | 135.58K | 8.00K | 99.37K | 19.72K | 120.01K | 0.00 | 0.00 | 0.00 | 0.00 | 95.14K | 1.74M | 573.54K | 11.34K | 25.89K | 0.00 |
| Depreciation & Amortization | 751.94K | 504.30K | 491.41K | 481.13K | 259.74K | 328.11K | 83.52K | 16.58K | 0.00 | 0.00 | 8.33K | 0.00 | 0.00 | 166.64K | 35.47K | 47.60K | 40.48K | 0.00 |
| EBITDA | -14.69M | -15.16M | -12.00M | -13.04M | -8.45M | -8.54M | -8.40M | -6.09M | -3.80M | -5.35M | -756.87K | -343.94K | -216.95K | -855.93K | -1.34M | -1.57M | -55.88K | 0.00 |
| EBITDA Ratio | -455.34% | -303.90% | -404.87% | -443.15% | 134.22% | -2,875.65% | -6,984.90% | -277,354.48% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -243.40% | -63.32% | -82.21% | -2.13% | 0.00% |
| Operating Income | -15.23M | -14.63M | -12.49M | -9.50M | 621.07K | -8.86M | -8.48M | -6.11M | -3.80M | -5.35M | -765.21K | -343.94K | -216.95K | -1.02M | -1.37M | -1.61M | -96.37K | 0.00 |
| Operating Income Ratio | -449.72% | -314.75% | -421.46% | -466.80% | 94.64% | -2,986.19% | -7,054.36% | -278,109.10% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -290.78% | -65.00% | -84.70% | -3.67% | 0.00% |
| Total Other Income/Expenses | -5.90M | -1.64M | -1.59M | -7.48M | 6.84M | -1.94M | -1.21M | -2.01M | -166.94K | -2.65K | -27.35K | 53.06K | -232.49K | -2.16M | -573.54K | -11.34K | 14.60K | 0.00 |
| Income Before Tax | -21.13M | -17.14M | -13.53M | -18.81M | -1.88M | -8.99M | -8.50M | -6.23M | -3.80M | -5.34M | -766.90K | -290.88K | -449.44K | -3.18M | -1.95M | -1.63M | -81.77K | 0.00 |
| Income Before Tax Ratio | -623.80% | -368.81% | -456.71% | -924.70% | -285.93% | -3,029.02% | -7,070.76% | -283,571.37% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -904.30% | -92.17% | -85.30% | -3.11% | 0.00% |
| Income Tax Expense | 2.02K | -1.36M | -27.28K | 1.21M | 27.32K | -1.04K | -1.63M | -1.73M | 0.00 | 0.00 | -25.66K | 0.00 | -117.28K | 2.14M | 728.55K | 251.84K | 2.57M | 0.00 |
| Net Income | -20.82M | -16.77M | -13.97M | -19.36M | -2.31M | -8.25M | -8.14M | -6.16M | -3.80M | -5.34M | -766.90K | -290.88K | 1.94M | -2.63M | -1.95M | -1.88M | -81.77K | 0.00 |
| Net Income Ratio | -614.71% | -360.79% | -471.33% | -951.67% | -351.91% | -2,778.31% | -6,773.31% | -280,252.34% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -748.06% | -92.17% | -98.51% | -3.11% | 0.00% |
| EPS | -7.07 | -6.53 | -7.33 | -14.01 | -1.91 | -7.33 | -8.43 | -10.20 | -13.43 | -33.40 | -11.83 | -11.25 | 156.00 | -326.13 | -244.95 | -236.36 | -11.07 | 0.00 |
| EPS Diluted | -7.07 | -6.53 | -7.33 | -14.01 | -1.91 | -7.33 | -8.43 | -10.20 | -13.43 | -33.37 | -11.83 | -11.25 | 156.00 | -326.13 | -244.95 | -236.36 | -11.07 | 0.00 |
| Weighted Avg Shares Out | 2.95M | 2.57M | 1.91M | 1.38M | 1.21M | 1.13M | 966.34K | 603.56K | 282.81K | 159.81K | 64.81K | 25.86K | 12.40K | 8.07K | 7.94K | 7.94K | 7.39K | 7.39K |
| Weighted Avg Shares Out (Dil) | 2.95M | 2.57M | 1.91M | 1.38M | 1.21M | 1.13M | 966.34K | 603.56K | 282.81K | 159.96K | 64.81K | 25.86K | 12.40K | 8.07K | 7.94K | 7.94K | 7.39K | 7.39K |
MGC Pharmaceuticals signs supply and distribution agreement with Swiss PharmaCan for ArtemiC™ Rescue
MGC Pharmaceutical to start new In-vitro cannabinoid study on glioblastoma brain cancer treatment using nano-delivery platform
Source: https://incomestatements.info
Category: Stock Reports